文献速递食管与纵隔外科

临床T2 N0 M0食管癌:识别分期上调的预测因素

Clinical T2 N0 M0 Esophageal Cancer: Identifying Predictive Factors of Upstaging.
PubMed 文献 · Ann Thorac Surg · 2024-02-01

研究纳入2000至2020年间60例接受一期手术的cT2 N0 M0食管癌患者,评估术前影像、临床及内镜因素对病理分期上调的预测价值。结果显示吞咽困难(P=0.003)和肿瘤最大标准化摄取值(P=0.048)是分期上调的预测因素,联合预测价值可达75%。作者认为具有吞咽困难和高最大标准化摄取值(≥5)的患者应考虑新辅助治疗。

要点

  • 60例cT2 N0 M0食管癌患者中,36例(60%)术后病理分期上调。
  • 吞咽困难(P=0.003)和肿瘤最大标准化摄取值(P=0.048)可预测分期上调。
  • 两因素联合预测分期上调的价值可达75%。

核心结论

  • 吞咽困难和高肿瘤最大标准化摄取值(≥5)可预测cT2 N0 M0食管癌患者存在更晚期病变,这些患者应考虑新辅助治疗。

研究设计与样本

  • 回顾性研究,纳入2000年至2020年间1579例接受食管切除术的食管癌患者中的60例因cT2 N0 M0接受一期手术者,中位年龄62.5岁,78%(n=47)为男性。

主要发现

  • 60例患者中,8例(13%)术后病理为T2 N0 M0,16例(27%)病理分期下调,36例(60%)病理分期上调。
  • 36例分期上调患者中,7例(19%)基于病理T分期上调,14例(39%)基于病理N分期上调,15例(42%)基于T和N分期同时上调。
  • 吞咽困难(P=0.003)和肿瘤最大标准化摄取值(P=0.048)是分期上调的预测因素,联合预测价值可达75%。

关键数值与推荐

  • 吞咽困难P=0.003,肿瘤最大标准化摄取值P=0.048,联合预测价值75%。

临床怎么用

  • 作者认为,对于cT2 N0 M0食管癌患者,若存在吞咽困难和肿瘤最大标准化摄取值≥5,应考虑新辅助治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inaccuracy of clinical staging renders management of clinical T2 N0 M0 (cT2 N0 M0) esophageal cancer difficult. When an underlying advanced-stage disease is understaged to cT2 N0 M0, patients miss the opportunity to gain the potential benefits of neoadjuvant therapy. This study aimed to identify preoperative factors that predict underlying advanced-stage esophageal cancer. METHODS: From 2000 to 2020, 1579 patients with esophageal cancer underwent esophagectomy. Sixty patients who underwent upfront surgery for cT2 N0 M0 esophageal cancer were included in this study. The median age was 62.5 years, and 78% (n = 47) of these patients were male. Radiologic, clinical, and endoscopic factors were evaluated as preoperative markers. The Fisher exact and the Wilcoxon rank sum tests were used for categoric and continuous variables, respectively. Random forest classification was used to identify preoperative factors for predicting upstaging and downstaging. RESULTS: Of the 60 patients, 8 (13%) were found to have pathologic T2 N0 M0 esophageal cancer. Sixteen (27%) patients had cancer that was pathologically downstaged, and 36 (60%) had upstaged disease. Seven (19%) patients had upstaged cancer on the basis of the pathologic T stage, 14 (39%) had upstaging on the basis of the pathologic N stage, and 15 (42%) had upstaging on the basis of both T and N stages. Dysphagia (P = .003) and tumor maximum standardized uptake value (P = .048) were predictors of upstaging, with a combined predictive value of up to 75%. CONCLUSIONS: The presence of dysphagia and of high maximum standardized uptake value (≥5) of the tumor is predictive of more advanced underlying disease for patients with cT2 N0 M0 esophageal cancer, and these patients should be considered for neoadjuvant therapy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Tasnim S, Raja S, Blackstone EH, et al. Clinical T2 N0 M0 Esophageal Cancer: Identifying Predictive Factors of Upstaging. Ann Thorac Surg. 2024. PMID: 38307482. doi:10.1016/j.athoracsur.2024.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。